TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06244797

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: L-PRF and H-PRF
Description: Blood (10 ml) will be taken from the patient with the help of an intraket in the arm or hand of appropriate size and size. Then, the blood sample taken will be placed in the PRF device for centrifugation and the sample will be centrifuged. According to the type of PRF, the centrifuge settings will be changed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: L-PRF and H-PRF
Description: Blood (10 ml) will be taken from the patient with the help of an intraket in the arm or hand of appropriate size and size. Then, the blood sample taken will be placed in the PRF device for centrifugation and the sample will be centrifuged. According to the type of PRF, the centrifuge settings will be changed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: L-PRF and H-PRF
Description: Blood (10 ml) will be taken from the patient with the help of an intraket in the arm or hand of appropriate size and size. Then, the blood sample taken will be placed in the PRF device for centrifugation and the sample will be centrifuged. According to the type of PRF, the centrifuge settings will be changed.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Impacted Tooth Removal
Description: All patients will be operated on by the same surgeon using the same procedure in order to ensure standardization. Following the administration of 2% articaine with 1:200,000 adrenalin for the inferior alveolar and buccal nerve blocks, a full-thickness mucoperiosteal flap will be raised, and the tooth will be extracted. Following the extraction of the tooth, sterile saline irrigation will be used in the socket, and bleeding control measures will be taken.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Impacted Tooth Removal
Description: All patients will be operated on by the same surgeon using the same procedure in order to ensure standardization. Following the administration of 2% articaine with 1:200,000 adrenalin for the inferior alveolar and buccal nerve blocks, a full-thickness mucoperiosteal flap will be raised, and the tooth will be extracted. Following the extraction of the tooth, sterile saline irrigation will be used in the socket, and bleeding control measures will be taken.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Impacted Tooth Removal
Description: All patients will be operated on by the same surgeon using the same procedure in order to ensure standardization. Following the administration of 2% articaine with 1:200,000 adrenalin for the inferior alveolar and buccal nerve blocks, a full-thickness mucoperiosteal flap will be raised, and the tooth will be extracted. Following the extraction of the tooth, sterile saline irrigation will be used in the socket, and bleeding control measures will be taken.
Study: NCT05466214

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conjoint Behavioral Consultation (CBC)
Description: Within the treatment group, CBC will be integrated into how a school-based specialist works with families and teachers of children with or at risk of severe emotional disturbance.
Study: NCT05297968

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir Phosphate For Oral Suspension/Tamiflu
Description: the subjects randomly received single oral administration of Oseltamivir Phosphate For Oral Suspension/Tamiflu 75mg (6mg/ml,12.5ml)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir Phosphate For Oral Suspension
Description: the subjects randomly received single oral administration of Oseltamivir Phosphate For Oral Suspension 75mg (6mg/ml,12.5ml)
Study: NCT05162066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX9930
Description: Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX9930
Description: Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX9930
Description: Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily
Study: NCT05789238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ANVISA
Description: Products carrying front-of-package labels based on Brazil's Health Regulatory Agency (ANVISA's) nutrient profile model

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAHO
Description: Products carrying front-of-package labels based on the Pan-American Health Organization (PAHO's) nutrient profile model
Study: NCT05061056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Russian current 10%
Description: Russian current with 2500 Hz, modulated in bursts of 50 Hz, 200 µs and 10% duty cycle - 2 ms bursts and 18 ms interbusrts
Study: NCT04775511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat Therapy with heating pads
Description: 20 minutes of heating pads will be applied to the medial gastrocnemius muscle, followed by gastrocnemius muscle stretching for 20 minutes. While the patient is lying in a prone position the towel, which is located between the skin and heating pads, and heating pads will be placed on the gastrocnemius muscle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Therapy with ice packs
Description: 20 minutes of ice packs will be applied to the medial gastrocnemius muscle, followed by gastrocnemius muscle stretching for 20 minutes. While the patient is lying in a prone position the towel, which is located between the skin and ice packs, and ice packs will be placed on the gastrocnemius muscle.

Intervention type: OTHER
Group type: OTHER
Intervention: Stretching Exercises
Description: 20 minutes of stretching exercises will be applied. In stretching exercises, stretching will be done for 30 seconds. The stretching exercises, which contain the maximal tension to the ankle, will be performed by the same physiotherapist while the patient is in the supine position, hip and knee extension.
Study: NCT06113874

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hurriseal desensitizer
Description: Patients will receive Hurriseal desensitizing agent and universal bond and composite.~Cavities will be restored with light-cured composite resin following the application of bonding agent.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluma desensitizer
Description: Patients will receive Gluma desensitizing agent and universal bond and composite.~Cavities will be restored with light-cured composite resin following the application of bonding agent.
Study: NCT05242250

Intervention type: DEVICE
Intervention: Catheter Ablation
Description: Ablation RF technologies manufactured by Abbott.

Intervention type: DEVICE
Intervention: Catheter Ablation
Description: Ablation RF technologies manufactured by Abbott.

Intervention type: DEVICE
Intervention: Catheter Ablation
Description: Ablation RF technologies manufactured by Abbott.
Study: NCT04654858

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct composite restorations
Description: bulk-fill composite (Filtek BulkFlow, 3M Espe) will be used aftar infiltration or block anaesthesia for affected molar,following by carious tissue removal. Marginal bevelling of enamel will be performed. A universal adhesive (Scotchbond Universal, 3M Espe) will be placed after selective enamel etching A bulk-fill composite will be used and covered using a nanohybrid composite, (Filtek XT, 3M Espe).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct composite restorations
Description: bulk-fill composite (Filtek BulkFlow, 3M Espe) will be used aftar infiltration or block anaesthesia for affected molar,following by carious tissue removal. Marginal bevelling of enamel will be performed. A universal adhesive (Scotchbond Universal, 3M Espe) will be placed after selective enamel etching A bulk-fill composite will be used and covered using a nanohybrid composite, (Filtek XT, 3M Espe).
Study: NCT06530784

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: After the completion of screening, the subjects received cryoablation treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody and bevacizumab
Description: Three days after cryoablation, the patients receive intravenous infusion of Tislelizumab (200mg, with 100mL of normal saline) and Bevacizumab (dose 15mg/kg, with 100mL of normal saline) .The patients will receive Tislelizumab (200 mg, with 100 mL of normal saline) and Bevacizumab (15 mg/kg, with 100 mL of normal saline) once every 3 weeks until disease progression.
Study: NCT05061056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Russian current 20%
Description: Russian current with 2500 Hz, modulated in bursts of 50 Hz, 200 µs and 20% duty cycle - 4 ms bursts and 16 ms interbusrts

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aussie current 10%
Description: Aussie current with 1000 Hz, modulated in bursts of 50 Hz, 500 µs and 10% duty cycle - 2 ms bursts and 18 ms interbusrts

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aussie current 20%
Description: Aussie current with 1000 Hz, modulated in bursts of 50 Hz, 500 µs and 20% duty cycle - 4 ms bursts and 16 ms interbusrts
Study: NCT06140264

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture dry needle
Description: The muscles that have been treated iliocostalis lumborum, quadratus lumborum, gluteus medius and piriformis muscles. The patients received 2 sessions per week for 2 weeks.
Study: NCT06501274

Intervention type: DEVICE
Group type: OTHER
Intervention: capsule sponge
Description: capsule sponge sampling device of the oesophagus
Study: NCT03825965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPL-001 (CBD: THC 25:1)
Description: 25:1 cannabidiol (CBD): tetrahydrocannabinol (THC) oral formulation, with a concentration of 50 mg/mL CBD and 2 mg/mL THC, oil- Liquid for oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oil for oral use
Description: Placebo is Medium-chain triglycerides oil with identical features (in appearance, flavour, and odour) to the MPL-001 oil.
Study: NCT05791292

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation
Description: To evaluate hand grip strength, neck discomfort, arm, shoulder and hand problems, and overall quality of life.

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation
Description: To evaluate hand grip strength, neck discomfort, arm, shoulder and hand problems, and overall quality of life.
Study: NCT04710329

Intervention type: DRUG
Intervention: Ascorbic acid
Description: The daily administration of 6 grams of vitamin C intravenously in 4 equal doses every 6 hours occurred and the treatment lasted 96 hours. Vials containing 1.5 gr vitamin C were placed in 100 cc 5% dextrose and infused intravenously in 30-60 minutes. Prepared serum bottles and sets are wrapped with aluminum foil in order to protect them from sunlight.

Intervention type: DRUG
Intervention: Ascorbic acid
Description: The daily administration of 6 grams of vitamin C intravenously in 4 equal doses every 6 hours occurred and the treatment lasted 96 hours. Vials containing 1.5 gr vitamin C were placed in 100 cc 5% dextrose and infused intravenously in 30-60 minutes. Prepared serum bottles and sets are wrapped with aluminum foil in order to protect them from sunlight.
Study: NCT05381129

Intervention type: OTHER
Group type: OTHER
Intervention: Detection of Pain, Quality of Life, Sleep and Functioning
Description: All patients will be evaluated for allodynia, quality of life, headache-related disability, and sleep quality.

Intervention type: OTHER
Group type: OTHER
Intervention: Detection of Pain, Quality of Life, Sleep and Functioning
Description: All patients will be evaluated for allodynia, quality of life, headache-related disability, and sleep quality.

Intervention type: OTHER
Group type: OTHER
Intervention: Temporomandibular joint dysfunction
Description: Patients with jaw complaints will be evaluated for temporomandibular joint dysfunction.
Study: NCT06502093

Intervention type: OTHER
Intervention: Observational Malnutrition Screening and Foodservice Satisfaction
Description: Patients asked Acute Care Hospital Foodservice Patient Satisfaction Questionnaire and malnutrition risk assessed with NRS-2002 screening tool.
Study: NCT05545956

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hand Wrung
Description: Hand wrung refers to manually wringing surgical sponges by hand.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProCell Wrung
Description: ProCell wrung refers to automated wringing surgical sponges by an FDA approved suction device (ProCell).
Study: NCT04280354

Intervention type: OTHER
Intervention: compare data patterns by data-driven algorithms to determine sepsis
Description: compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to reliably determine sepsis
Study: NCT05856903

Intervention type: DIAGNOSTIC_TEST
Intervention: ACT
Description: ACT will be measured :~* after in vitro spiking with unfractionated heparin of blood samples from severe hemophilia A patients already treated with emicizumab~* after in vitro spiking with unfractionated heparin with or without emicizumab of blood samples from healthy volunteers

Intervention type: DIAGNOSTIC_TEST
Intervention: ACT
Description: ACT will be measured :~* after in vitro spiking with unfractionated heparin of blood samples from severe hemophilia A patients already treated with emicizumab~* after in vitro spiking with unfractionated heparin with or without emicizumab of blood samples from healthy volunteers
Study: NCT06173700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web-based group problem solving and coping training
Description: The group included one-hour, weekly Zoom sessions, that were facilitated by an occupational therapy doctoral candidate (first author) for 7 consecutive weeks. During the first session, the candidate explained adaptive and maladaptive coping strategies and asked each participant to identify one adaptive coping strategy that they currently use and will continue to use in the future. The candidate then explained the FOCUS problem-solving approach. For each session afterward, the candidate presented a topic-related scenario for parents to identify an effective solution using the FOCUS steps (APA, 2011). Parent-chosen topics included recreation, assistive technology, motivating and advocating, physical activity, skin integrity, and adaptive fashion. The general process of the meetings is presented in Figure 1. After every meeting the candidate sent out a summary of resources that were discussed during the meeting, ultimately putting them all together in an Empowering Caregiver Guide.
Study: NCT06532240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Methylene Blue 100mg will be diluted in 40ml 5% dextrose solution.The patient will receive Methylene Blue bolus with a dose of 1 mg/kg (Ideal Body Weight) over 30 minutes,followed by 0.25mg/kg/h as a continuous infusion for 6 hours for 5 days or discontinution of norepinephrine or until ICU discharge, whichever occurred first.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An identical volume of 5% dextrose solution from the placebo drug bag will be administered to patients using the same protocol as intervention arm.
Study: NCT04280354

Intervention type: OTHER
Intervention: compare data patterns by data-driven algorithms to predict sepsis-related mortality
Description: compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to to predict sepsis-related mortality

Intervention type: OTHER
Intervention: compare data patterns by data-driven algorithms to predict sepsis-related mortality
Description: compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to to predict sepsis-related mortality
Study: NCT06086197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
Description: Anlotinib: 12mg d1\~14 po qd, Rituximab: 375mg/m2 d1, gemcitabine: 1000mg/m2 d1 and d8, oxaliplatin: 130mg/m2 d1;~For subjects ≥75 years of age, appropriate reduction of chemotherapy drugs (not less than 75% of the standard dose, or withdrawal of day 8 gemcitabine) may be decided by the investigator.
Study: NCT06340009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mime therapy
Description: 1. Facial Massage~2. Frowning~3. Close eyes~4. Smile~5. Fish Face~6. Eyebrow raising~7. Breathing exercise~8. Blow cheeks~9. Mouth opening and closing.~10. Moving lips side to side~11. Blow a candle.~12. Nasal flaring~13. Chewing exercise~14. Rinse mouth~15. Speaking vowels~16. Fill mouth with water~17. Fill rubber balloon~18. Sucking water with straw

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: motor imagery
Description: 1. Raising your eyebrows~2. Showing angry face~3. Closing and opening eyes~4. Pouting~5. Blowing cheeks~6. Smiling~7. Nasal flaring~8. Blowing candle~9. Deviating lips side to side~10. Chewing something~11. Speaking vowels
Study: NCT04878367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Five active practices of living rules for responding to fine dust.
Description: 1. Check the fine dust weather forecast~2. Check the operation time and filter of the air purifier~3. Window ventilation~4. Inhalant is used or not~5. Bad fine dust: Refrain from going out
Study: NCT05229107

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cereset Research
Description: Device: Cereset Research The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
Study: NCT04221880

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hcl 0.25% Inj
Description: Ultrasound-guided erector spinae plane block with 20 ml %0.25 bupivacaine

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline Solution for Block
Description: Ultrasound-guided erector spinae plane block with 20 ml saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Solution for Block
Description: Ultrasound-guided erector spinae plane block with 20 ml saline

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline Solution intravenously
Description: Same volume saline solution bolus and infusion as Group Lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Solution intravenously
Description: Same volume saline solution bolus and infusion as Group Lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 1.5 mg / kg lidocaine iv. bolus and, 1.5mg / kg / h lidocaine iv. infusion
Study: NCT04677439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumatinib
Description: 600 mg of Flumatinib orally daily for 24 months
Study: NCT04475692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Repetitive, task-specific upper limb practice
Description: A self-directed upper limb intervention (implementing a self-selected dose). This intervention uses an adapted upper limb rehabilitation system to support repetitive upper limb training for stroke survivors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional care
Description: Conventional care is the standard care offered to stroke patients in their respective settings. In this context it is guided by Royal College of Physicians (2016). For the purposes of this work, conventional care encompasses any rehabilitation or support services accessed by participants within the primary or secondary care setting, including private therapy services, charity-led exercise groups etc. Conventional care will not be specified in the context of this work, as it is complex in nature and varies between settings.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional care
Description: Conventional care is the standard care offered to stroke patients in their respective settings. In this context it is guided by Royal College of Physicians (2016). For the purposes of this work, conventional care encompasses any rehabilitation or support services accessed by participants within the primary or secondary care setting, including private therapy services, charity-led exercise groups etc. Conventional care will not be specified in the context of this work, as it is complex in nature and varies between settings.
Study: NCT03416361

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 4000IU Vitamin D3
Description: Chewable blackcurrant flavoured tablets (two per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 4000IU Vitamin D3
Description: Chewable blackcurrant flavoured tablets (two per day)
Study: NCT05834010

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiome Transplant
Description: Fecal matter from healthy age/sex matched established and screened donors, recruited from the Danish Blood-donor system
Study: NCT05573971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: with verbal encouragement
Description: Each athlete swam a maximal 200m freestyle trial in two different conditions: one trial with verbal encouragement and the other without verbal encouragement
Study: NCT04755946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: adding one tablet of roflumilast 500 mcg to the standard ACEI (captopril) for diabetic nephropathy management

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05509868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBK_L1704 0.35mg
Description: The subject will receive PBK_L1704 0.35mg/ml by PCA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBK_L1704 0.5mg
Description: The subject will receive PBK_L1704 0.5mg/ml by PCA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subject will receive placebo by PCA
Study: NCT04500847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtriva Capsule
Description: 200mg daily oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200mg daily oral dose